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Introduction {#sec1}
============

Adult muscle stem cells, also known as muscle satellite cells, which are the resident tissue stem cells of skeletal muscle, provide myonuclei for postnatal muscle growth and for maintenance and regeneration in adults ([@bib4], [@bib32], [@bib37], [@bib57]). Satellite cells are located between the basal lamina and the plasmalemma of myofibers ([@bib30]). Postnatal myogenesis comprises the activation of quiescent satellite cells, the proliferation of myoblasts (activated satellite cells), and the fusion of myoblasts into multinucleated fibers. Myogenesis is a complex process that is controlled by the spatiotemporal expression of transcription factors including myogenic regulatory factors (MRFs) ([@bib5], [@bib35], [@bib54]).

The ubiquitin-proteasome pathway is responsible for most protein degradation in mammalian cells ([@bib9]). Proteasomal degradation is mediated by the 26S proteasome, which is an ATP-dependent protease complex that is present in both the cytoplasm and nucleus. The ubiquitin-proteasome pathway has emerged as a central player in the regulation of several diverse cellular processes and functions by catalyzing the selective degradation of short-lived regulatory proteins as well as abnormal proteins. Thus, understanding the role of the proteasome in each cell and tissue type is essential for comprehending the maintenance of homeostasis.

The 26S proteasome is composed of one proteolytically active cylinder-shaped particle (the 20S proteasome) and ATPase-containing complexes (the 19S cap complexes) ([@bib3]). The 19S cap complex unfolds ubiquitin-conjugated proteins to allow their entry into the 20S cylindrical particle. It also contains several putative ATPases, such as Rpt1--6. These subunits form a large family with a highly conserved ATPase domain ([@bib39]). Rpt3, also known as PSMC4, is an essential subunit of the 26S proteasome and is required for the degradation of most proteasomal substrates. In particular, *Rpt3*-deficient mice die before implantation due to a defect in blastocyst development ([@bib39]); this indicates that *Rpt3* is essential for survival. Interestingly, an insertion/deletion variant in intron 5 of the *Rpt3* gene was frequently found in a cohort of patients with Parkinson\'s disease ([@bib29]). To explore the organ- and cell-specific role of the proteasome, we generated proteasome-deficient mice by targeting *Rpt3* ([@bib25], [@bib46]). Previously, we found that conditional knockout of *Rpt3* in motor neurons results in locomotor dysfunction, which was accompanied by progressive motor neuron loss and gliosis in mice ([@bib46]).

Recently, we also reported that muscle-specific *Rpt3* knockout mice exhibit proteasome insufficiency, leading to obvious muscle atrophy ([@bib25]). Furthermore, centrally nucleated regenerating fibers were observed in muscle-specific *Rpt3* knockout mice, indicating the involvement in muscle regeneration. However, it remains unclear how the proteasome system regulates satellite cells. Here, we investigated the pathophysiological effect of proteasome insufficiency induced by depletion of *Rpt3* on satellite cells *in vivo* and *in vitro* by using satellite cell-specific *Rpt3*-knockout mice.

Results {#sec2}
=======

Proteasome Activity in Skeletal Muscle during Muscle Regeneration {#sec2.1}
-----------------------------------------------------------------

As the first step to determine proteasome activity in muscle during skeletal muscle regeneration, we induced skeletal muscle injury by injecting cardiotoxin (CTX) into the tibialis anterior (TA) muscle in mice. First, we analyzed the regenerative capacity of C57BL/6J mice over time ([Figure S1](#mmc1){ref-type="supplementary-material"}A). On days 14 and 30 after injury, the weight of CTX-injected muscles was significantly increased compared with that of intact muscles ([Figure S1](#mmc1){ref-type="supplementary-material"}B). At 30 days post injury, the mean TA muscle weight per body weight was also increased compared with that of intact muscle ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Furthermore, histological analysis revealed extensive muscle damage and the infiltration of inflammatory cells into the muscle at 3 days post CTX injection, whereas centrally nucleated regenerating fibers began to be visible at day 7 post injury ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Following muscle injury, satellite cells start to express *MyoD* and become myoblasts (PAX7+/MYOD + cells) to proliferate ([@bib57]). Quantitative PCR (qPCR) analysis confirmed that mRNA levels of *MyoD*, *Pax7*, and *Myh3*, markers of regenerating fibers, peaked at day 3 post injury ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

We next examined the proteasome system during regeneration after CTX-induced muscle injury. The ubiquitin-proteasome system degrades most long- and short-lived normal and abnormal intracellular proteins ([@bib9], [@bib18]). We used lysates from regenerating muscle tissue to evaluate chymotrypsin-like and trypsin-like proteasome activities during muscle regeneration. Chymotrypsin-like and trypsin-like proteasome activities drastically increased to a peak level at 3 days post injury, progressively declined until day 14, and then returned to levels comparable to those observed in uninjured control tissues by 30 post injury ([Figures 1](#fig1){ref-type="fig"}A and 1B). Because most proteasomal substrates must be ubiquitinated before degradation ([@bib42]), we analyzed ubiquitinated proteins during muscle regeneration by immunoblotting. Consistent with the proteasomal activities, we showed that the amount of ubiquitinated proteins increased, peaking at 3 days after injury and then returning to basal levels by 30 days post injury ([Figure 1](#fig1){ref-type="fig"}C). Because chymotrypsin-like and trypsin-like proteasome activity dramatically increased to a peak level 3 days after injury ([Figure 1](#fig1){ref-type="fig"}B), we then examined proteasome activity in only myocytes, excluding non-muscle cells, such as inflammatory cells, on day 3 post injury. At this time point, chymotrypsin-like and trypsin-like proteasome activities were significantly higher in myoblasts from injured animals, compared with those from control mice ([Figures 1](#fig1){ref-type="fig"}D, 1E, [S1](#mmc1){ref-type="supplementary-material"}F, and S1G). These results showed that proteasome activity is dramatically increased in skeletal muscle and myoblasts during the early phase of muscle regeneration.Figure 1Proteasome Activity in Skeletal Muscle during Muscle Regeneration(A) Time course for CTX treatment and tissue harvesting.(B) Chymotrypsin-like and trypsin-like proteasome activities (relative to those in intact tissue) in tibialis anterior (TA) muscles at 3, 7, and 14 days after injury are shown. Data represent means ± SEM (t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus intact; n = 3--5 per group). IU, international units.(C) Immunoblotting analysis of ubiquitin in the TA muscles at 3, 7, and 14 days post injury. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001 versus intact; n = 3--5 per group).(D) Time course analysis of satellite cells at 3 days after injury.(E) Chymotrypsin-like and trypsin-like proteasome activities (relative to those in intact satellite cells) in satellite cells sorted from TA muscles at 3 days post injury. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001 versus intact satellite cells; n = 4--5 per group). IU, international units.See also [Figures S1](#mmc1){ref-type="supplementary-material"}.

Satellite Cell-specific *Rpt3*-Knockout Mice Exhibit No Obvious Phenotype in Muscle {#sec2.2}
-----------------------------------------------------------------------------------

To investigate the function of the proteasome system in satellite cells, we generated satellite cell-specific *Rpt3* conditional knockout (*Rpt3*-scKO) mice by crossing *Pax7*^*CreERT2*^ mice ([@bib26]) with *Rpt3*^*f/f*^ mice ([@bib25], [@bib46]). Previously, we reported that deficiency of *Rpt3* in skeletal muscle or motor neurons causes proteasome insufficiency ([@bib25], [@bib46]). First, we examined the expression levels of *Rpt3* in muscle stem cells during proliferation and differentiation. Upon activation, muscle satellite cells proliferate, downregulate *Pax7*, and differentiate ([@bib24], [@bib57]). *Rpt3* gene expression in satellite cell-derived myoblasts did not differ during the proliferation and differentiation processes ([Figure S2](#mmc1){ref-type="supplementary-material"}). Genetic inactivation of *Rpt3* was induced by repeated intraperitoneal injection of tamoxifen (Tmx) into adult *Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^ mice, using Tmx-treated *Rpt3*^*f/f*^ littermates as the wildtype control ([Figure 2](#fig2){ref-type="fig"}A). Following Tmx treatment *in vivo*, *Rpt3* expression was significantly reduced in satellite cells ([Figure 2](#fig2){ref-type="fig"}B). In addition, chymotrypsin-like and trypsin-like proteasome activities were significantly lower in satellite cells from *Rpt3*-scKO mice ([Figure 2](#fig2){ref-type="fig"}C). Moreover, *Rpt3* gene knockdown was performed in the C2C12 myoblast cell line ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Two small interfering RNAs (siRNAs) were used and siRNA (\#2) resulted in a greater than 90% reduction in *Rpt3* expression ([Figure S3](#mmc1){ref-type="supplementary-material"}B), and thus was used in further experiments. Evaluation of proteasome function revealed that chymotrypsin-like and trypsin-like protease activities were significantly decreased 48 and 72 hr after gene knockdown ([Figure S3](#mmc1){ref-type="supplementary-material"}C). These results revealed the efficiency of the satellite cell-specific *Rpt3* conditional knockout in our mouse model.Figure 2Satellite Cell-specific *Rpt3*-Knockout Mice Exhibit No Obvious Skeletal Muscle Phenotype(A) Time course for tamoxifen (Tmx) treatment and tissue harvesting. Con indicates *Rpt3*^*f/f*^ mice and scKO indicates satellite cell-specific *Rpt3*-knockout mice (*Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^).(B) Relative expression of *Rpt3* mRNA in freshly isolated satellite cells derived from Con and scKO mice after Tmx injection. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001; n = 4 per group). AU, arbitrary units.(C) Chymotrypsin-like and trypsin-like proteasome activities (relative to Con) in freshly isolated satellite cells derived from Con and scKO mice after Tmx injection. Data represent means ± SEM (t test: ^∗∗^p \< 0.01; n = 4--5 per group). IU, international units.(D) Change in body weight (g) after Tmx injection. Data represent mean ± SD (NS, statistically nonsignificant, n = 5--10 per group).(E) Change in tibialis anterior (TA) muscle weight (g) at 2 months after Tmx injection. Data represent mean ± SD (NS, statistically nonsignificant, n = 4--6 per group).(F) H&E staining of intact TA muscle 2 months after Tmx injection. Scale bar, 50 μm. Also shown in [Figure S1](#mmc1){ref-type="supplementary-material"}D.(G) Endurance time(s) of Con and scKO mice. Data represent mean ± SD (NS, statistically nonsignificant, n = 4--6 per group).See also [Figures S2--S4](#mmc1){ref-type="supplementary-material"}.

Next, we investigated the effect of *Rpt3* deficiency in satellite cells on skeletal muscle *in vivo*. There was no change in body weight between control and *Rpt3*-scKO mice from 1 to 8 months after Tmx treatment ([Figure 2](#fig2){ref-type="fig"}D). There was also no difference in TA muscle weight ([Figure 2](#fig2){ref-type="fig"}E) and H&E staining of muscle cross sections ([Figure 2](#fig2){ref-type="fig"}F) 2 months after Tmx treatment. Other than limb muscles, in the diaphragm, there was no difference in the H&E staining of muscle cross sections and muscle cross-sectional area, 1 month after Tmx treatment ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C). Furthermore, when we performed an endurance test to investigate muscle function, there was no significant difference between control and *Rpt3*-scKO mice ([Figure 2](#fig2){ref-type="fig"}G). These results suggest that satellite cell-specific *Rpt3* knockout has no obvious effect on intact muscle in mice.

Satellite Cell-specific *Rpt3*-scKO Mice Are Associated with a Remarkable Defect in Regeneration {#sec2.3}
------------------------------------------------------------------------------------------------

To evaluate the role of *Rpt3* in satellite cells during muscle regeneration *in vivo*, we genetically inactivated *Rpt3* via five daily intraperitoneal injections of Tmx into *Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^ mice. Intramuscular injection of CTX was performed to induce regeneration of the TA muscle after 2 days of Tmx treatment ([Figure 3](#fig3){ref-type="fig"}A). We showed the muscle weight was markedly decreased in *Rpt3*-scKO mice after regeneration compared with that in control mice at day 7 and 14 post CTX treatment ([Figures 3](#fig3){ref-type="fig"}B--3D). Correspondingly, histological analysis confirmed a significant defect in muscle regeneration accompanied by a considerable number of infiltrating inflammatory cells in *Rpt3*-scKO mice at day 14 after CTX treatment, although efficient muscle regeneration accompanied by centrally nucleated myofibers was observed in control mice ([Figure 3](#fig3){ref-type="fig"}E). Immunohistochemistry also revealed incomplete regeneration with marked fibrosis at day 14 post CTX treatment in *Rpt3*-scKO mice ([Figure 3](#fig3){ref-type="fig"}F). In addition, the cross-sectional area of the regenerated fibers was decreased at day 14 post CTX treatment in *Rpt3*-scKO mice ([Figure 3](#fig3){ref-type="fig"}G). To evaluate muscle regeneration in the early phase, we assessed the expression of MYOD, which is a marker of myoblasts. MYOD+ cells were not frequently found in *Rpt3*-scKO mice 3 days after CTX treatment ([Figure 3](#fig3){ref-type="fig"}H). Taken together, our data indicate that the function of *Rpt3* in satellite cell is indispensable for muscle regeneration *in vivo*.Figure 3Satellite Cell-specific Deletion of *Rpt3* Prevents Muscle Regeneration(A) Time course for tamoxifen (Tmx) and cardiotoxin (CTX) treatment. Con indicates *Rpt3*^*f/f*^ mice and scKO indicates satellite cell-specific *Rpt3* knockout mice (*Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^).(B) Representative images of tibialis anterior (TA) muscles in Con and scKO mice.(C and D) Change in (C) muscle weight (mg) and (D) muscle weight (mg)/body weight (g). Data represent mean ± SEM (t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01 versus Con, n = 5--9 per group).(E) H&E staining of intact muscles and those injured by CTX injection, analyzed at 3, 7, and 14 days post injury. Scale bar, 50 μm.(F) Immunostaining of collagen I (red) and DAPI (blue) in TA muscle cryosections from scKO mice 14 days after injury. Scale bar, 100 μm. The y axis shows the mean collagen I fluorescence intensity (ratio). Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001; n = 5 per group).(G) Immunostaining of Laminin (red) and DAPI (blue) in TA muscle cryosections from scKO mice 14 days after injury. Scale bar, 100 μm. The y axis shows the mean cross-sectional area (CSA). Data represent means ± SD (t test: ^∗∗^p \< 0.01; n = 3 per group).(H) Immunostaining for MYOD (green), Laminin2α, and DAPI (blue) in TA muscle cryosections from scKO mice 3 days after injury. Scale bar, 50 μm. The y axis shows the relative ratio of MYOD-positive areas. Data represent means ± SD (t test: ^∗∗^p \< 0.01; n = 3 per group).

Loss of *Rpt3* Leads to a Depletion of the Quiescent Satellite Cell Pool {#sec2.4}
------------------------------------------------------------------------

Previous studies have confirmed the absolute necessity of PAX7-positive satellite cells for muscle regeneration ([@bib27], [@bib37], [@bib40], [@bib52]). Because muscle regeneration was impaired in *Rpt3*-scKO mice, we next examined how *Rpt3* knockout affects quiescent satellite cells in adult resting skeletal muscles. After 5 consecutive days of Tmx injection, we found a surprisingly rapid decline in the number of quiescent satellite cells in freshly isolated extensor digitorum longus (EDL) myofibers from *Rpt3*-scKO mice, but not in those from control mice ([Figures 4](#fig4){ref-type="fig"}A--4C). Specifically, 20% of quiescent satellite cells were lost within 5 days, 80% were lost within 10 days, and 90% were lost within 15 days in *Rpt3*-scKO mice ([Figure 4](#fig4){ref-type="fig"}C). Similarly, immunofluorescence staining for PAX7 and laminin in TA muscle cross sections indicated the robust ablation (90% loss) of PAX7+ quiescent satellite cells in *Rpt3*-scKO mice at day 15 after Tmx treatment ([Figures 4](#fig4){ref-type="fig"}D and 4E). In addition, immunofluorescence staining for M-cadherin, as another satellite cell marker in TA and diaphragm muscles, revealed a robust decrease in satellite cells in *Rpt3*-scKO mice ([Figures 4](#fig4){ref-type="fig"}F, 4G, [S4](#mmc1){ref-type="supplementary-material"}D, and S4E). We further analyzed the number of quiescent satellite cells in limb muscles by flow cytometry. We confirmed the rapid depletion of the satellite cell fraction in *Rpt3*-scKO mice, consistent with immunohistochemical analysis ([Figures 4](#fig4){ref-type="fig"}H, 4I, and [S5](#mmc1){ref-type="supplementary-material"}A--S5D). These results demonstrate that loss of *Rpt3* leads to depletion of quiescent satellite cells in adult resting muscle.Figure 4Rpt3 Inactivation Depletes the Satellite Cell Pool(A) Time course of tamoxifen (Tmx) treatment and tissue harvesting. Con indicates *Rpt3*^*f/f*^ mice and scKO indicates satellite cell-specific *Rpt3* knockout mice (*Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^).(B) Immunostaining for PAX7 (green) and DAPI (blue) in the extensor digitorum longus (EDL) single fiber 5 days after Tmx induction. Arrows indicate satellite cells. Scale bar, 50 μm.(C) Number of satellite cells per fresh EDL myofiber from Con and scKO mice 0--15 days after Tmx treatment. Data represent mean ± SEM (t test: ^∗^p \< 0.05, ^∗∗∗^p \< 0.001; day 0, n = 5; day 3, n = 4; day 5, n = 5; day 10, n = 5; day 15, n = 4 per group; more than 15 myofibers per animal).(D) Immunostaining for PAX7 (green), laminin (red), and DAPI (blue) in tibialis anterior (TA) muscle cryosections 5 days after Tmx treatment. Arrows indicate satellite cells. Scale bar, 20 μm.(E) Average number of satellite cells per 100 fibers. Data represent mean ± SEM (t test: ^∗∗^p \< 0.01; day 5, n = 4; day 15, n = 5 for each group).(F) Immunostaining for M-cadherin (green), Laminin2α (red), and DAPI (blue) in intact TA muscle cryosections from scKO mice. Arrows indicate satellite cells. Scale bar, 50 μm.(G) Average number of M-cadherin+ cells per 100 fibers. Data represent means ± SD (t test: ^∗∗∗^p \< 0.001; n = 3 per group).(H) Fluorescence-activated cell sorting profiles of mononuclear cells derived from Con and scKO mice 2 and 15 days after Tmx treatment. The gated profiles show satellite cell fractions (SM/C-2.6 + CD31− CD45− Sca1−) from Con and scKO mice.(I) Relative satellite cell fractions from Con and scKO mice. Data represent mean ± SEM (t test: ^∗∗∗^p \< 0.001; day 2, n = 4; day 15, n = 4 per group). SC, satellite cell.See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

Deficiency of *Rpt3* in Satellite Cells Results in Proliferative Defects during Muscle Regeneration *In Vivo* {#sec2.5}
-------------------------------------------------------------------------------------------------------------

To clarify whether the loss of satellite cells in *Rpt3*-scKO mice is caused by apoptosis, we performed apoptosis experiments using Cleaved-Caspase 3 *in vivo* ([Figure 5](#fig5){ref-type="fig"}A). Numbers of Cleaved-Caspase 3+ cells relative to PAX7+ cells were significantly increased in the intact TA muscle of *Rpt3*-scKO mice, 3 days after Tmx treatment ([Figure 5](#fig5){ref-type="fig"}B). Next, to elucidate cell proliferation in the satellite cells of *Rpt3*-scKO mice *in vivo*, we performed EdU incorporation assays and immunostaining for KI67, a proliferative marker that is not expressed in G0 cells ([Figure 5](#fig5){ref-type="fig"}C). The proliferative ability of intact TA muscle in *Rpt3*-scKO mice was not different from that in control mice ([Figures 5](#fig5){ref-type="fig"}D and 5E).Figure 5Deficiency of *Rpt3* in Satellite Cells Results in Proliferative Defects during Muscle Regeneration *In Vivo*(A) Time course for tamoxifen (Tmx) treatment and tissue harvesting. Con indicates *Rpt3*^*f/f*^ mice and scKO indicates satellite cell-specific *Rpt3* knockout mice (*Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^).(B) Immunostaining for Cleaved-Caspase3 (green), Pax7 (red), and DAPI (blue) in tibialis anterior (TA) muscle cryosections 3 days after Tmx treatment. Arrows indicate satellite cells. Scale bar, 10  μm. The y axis shows the ratio of Cleaved-Caspase3-positive cells to PAX7-positive cells. Data represent means ± SD (t test: ^∗∗^p \< 0.01; n = 3 per group).(C) Time course for Tmx treatment and tissue harvesting.(D) Immunostaining for EdU (green), M-cadherin (red), and DAPI (blue) in TA muscle cryosections, 3 days after Tmx treatment. Arrows indicate satellite cells. Scale bar, 10  μm. The y axis shows the ratio of EdU-positive cells to M-cadherin-positive cells. Data represent means ± SD (t test: NS, no significance; n = 3 per group).(E) Immunostaining for M-cadherin (green), KI67 (red), and DAPI (blue) in TA muscle cryosections, 3 days after Tmx treatment. Arrows indicate satellite cells. Scale bar, 10  μm. The y axis shows the ratio of KI67-positive cells to M-cadherin-positive cells. Data represent means ± SD (t test: NS, no significance; n = 3 per group).(F) Time course for Tmx treatment and tissue harvesting.(G) Immunostaining for EdU (green), M-cadherin (red), and DAPI (blue) in TA muscle cryosections, 3 days after injury. Scale bar, 50  μm. The y axis shows the number of EdU-positive and M-cadherin-positive cells per field. Data represent means ± SD (t test: ^∗∗^p \< 0.01; n = 3 per group).

Moreover, to examine the proliferative potential of *Rpt3*-scKO satellite cells during muscle regeneration, an EdU incorporation assay was performed ([Figure 5](#fig5){ref-type="fig"}F). EdU+ M-cadherin+ cells were significantly decreased in *Rpt3*-scKO mice when compared with the control mice ([Figure 5](#fig5){ref-type="fig"}G). These data suggested that the deficiency of *Rpt3* in satellite cells results in proliferative defects during muscle regeneration *in vivo.*

Deletion of *Rpt3* in Satellite Cells Induces a Proliferation Defect and Apoptosis {#sec2.6}
----------------------------------------------------------------------------------

We next focused on how the proliferative state of satellite cells is affected by proteasome dysfunction mediated by *Rpt3*-deficiency *in vitro*. Satellite cells isolated from *Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^ mice were plated and treated with 4-hydroxy tamoxifen (4OH-Tmx) for 2 days to genetically delete *Rpt3* in satellite cells ([Figure 6](#fig6){ref-type="fig"}A). Expression of *Rpt3* was suppressed by 85% in *Rpt3* KO satellite-cell-derived myoblasts compared with that in control myoblasts ([Figure 6](#fig6){ref-type="fig"}B). Cell proliferation was evaluated by performing EdU incorporation assays *in vitro*. The proliferative ability of *Rpt3*-deficient primary myoblasts was decreased compared with that in controls ([Figure 6](#fig6){ref-type="fig"}C). In addition, to investigate whether cell proliferation defects also occur after *Rpt3* knockdown in other cells, *Rpt3*-knockdown experiments were performed using primary fibroblasts ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Cell proliferation was suppressed in primary fibroblasts with *Rpt3*-knockdown compared with that in controls ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C).Figure 6Deletion of *Rpt3* in Satellite Cells Induces a Proliferation Defect and Apoptosis(A) Time course for tamoxifen (Tmx) treatment and tissue harvesting. Con indicates *Rpt3*^*f/f*^ mice and scKO indicates satellite cell-specific *Rpt3* knockout mice (*Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^).(B) Relative expression of *Rpt3* mRNA in *Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^ satellite cells treated with vehicle or 4OH-Tmx. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001; n = 3 per group). AU, arbitrary units.(C) Immunostaining for EdU (green) and DAPI (blue) in satellite cells treated with vehicle or 4OH-Tmx. Scale bar, 50  μm. The y axis shows the relative ratio of EdU-positive cells. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001; n = 4 per group).(D) Immunostaining for TUNEL (green) and DAPI (blue) in satellite cells treated with vehicle or 4OH-Tmx. Arrows indicate TUNEL-positive cells. Scale bar, 100  μm. The y axis shows the ratio of TUNEL-positive cells to DAPI-positive cells. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001; n = 3 per group).(E) Immunoblotting analysis of Cleaved-Caspase3 and GAPDH in satellite cells treated with vehicle or 4OH-Tmx.(F) Relative ratio of DAPI-positive cells from Con or scKO mice. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001; n = 3 per group).(G) Time course of Tmx treatment and tissue harvesting. Con siRNA indicates control siRNA transfection and *Rpt3* siRNA indicates *Rpt3* siRNA transfection.(H) Immunostaining for EdU (green) and DAPI (blue) in C2C12 cells after siRNA transfection. Scale bar, 50  μm. The y axis shows the relative ratio of EdU-positive cells. Data represent means ± SEM (t test: ^∗∗^p \< 0.01; n = 3 per group).(I) Immunostaining for TUNEL (green) and DAPI (blue) in C2C12 cells after siRNA transfection. Arrows indicate TUNEL-positive cells. Scale bar, 100  μm. The y axis shows the ratio of TUNEL-positive cells to DAPI-positive cells. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001; n = 3 per group).(J) Relative ratio of DAPI-positive cells. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001; n = 3 per group).See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.

We next asked if *Rpt3*-knockout-satellite cells can undergo myogenic differentiation. Two days after the induction of differentiation, control myoblasts already displayed an obviously elongated morphology, a hallmark of differentiation ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). In contrast, *Rpt3*-scKO primary myoblasts were mostly spherical ([Figure S7](#mmc1){ref-type="supplementary-material"}B), indicative of a differentiation defect. We further quantified the differentiation index, which measures the fraction of myonuclei that are located in myosin heavy chain (MyHC+)-expressing cells. Although greater than 50% of nuclei in the control were located in MyHC+ cells, only 15% of nuclei in *Rpt3*-scKO mice were found in MyHC+ cells ([Figure S7](#mmc1){ref-type="supplementary-material"}B).

To determine if the reduction in satellite cell-derived myoblasts proliferation was also due to cell death, apoptosis was evaluated by performing TUNEL assays. TUNEL-positive apoptotic cells were detected more frequently in primary myoblasts of *Rpt3*-scKO mice ([Figure 6](#fig6){ref-type="fig"}D). This was further supported by the upregulation of Cleaved-Caspase 3, an indicator of apoptosis, in *Rpt3*-inactivated primary myoblasts ([Figure 6](#fig6){ref-type="fig"}E). Consistent with these results, the number of cells was reduced in *Rpt3*-scKO mice compared with that in control mice ([Figure 6](#fig6){ref-type="fig"}F). Upon knockdown of *Rpt3*, proliferation and cell numbers decreased, whereas apoptotic cells were more frequently detected in *Rpt3*-ablated cells ([Figures 6](#fig6){ref-type="fig"}G--6J). These results demonstrate that proteasome dysfunction mediated by *Rpt3* deficiency in satellite cells induces a proliferation defect and apoptosis.

p53 Knockdown in *Rpt3*-Deficient Satellite Cells Rescues the Defect in Proliferation {#sec2.7}
-------------------------------------------------------------------------------------

We next investigated the molecular mechanism underlying *Rpt3* deficiency-induced dysfunction in activated satellite cells. To identify the pathways affected by *Rpt3* deficiency in an unbiased manner, we performed microarray analysis of quiescent satellite cells from control and *Rpt3*-scKO mice (accession number [GSE114354](ncbi-geo:GSE114354){#intref0010}). We identified 1,254 genes that were up- or downregulated with p values \< 0.05 ([Table S2](#mmc2){ref-type="supplementary-material"}). Significantly differentially expressed genes were imported into the DAVID v6.7 annotation tool, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed. The enrichment of specific pathway components into functionally regulated gene groups was characterized with reference to the KEGG pathway database. This analysis identified the top two categories as being related to the proteasome and p53 signaling pathways ([Figure 7](#fig7){ref-type="fig"}A).Figure 7p53 Knockdown in *Rpt3*-Deficient Satellite Cells Rescues the Defect in Proliferation(A) DAVID v6.7 functional annotation bioinformatics microarray analysis software was used to obtain KEGG pathway functional classification. Only KEGG pathway terms for classification that showed statistically significant differences, in terms of the number of differentially regulated genes (satellite cells from satellite cell-specific *Rpt3* mice versus satellite cells from control mice), are shown (p \< 0.05). The 1,254 significantly differentially regulated genes are shown in [Table S2](#mmc2){ref-type="supplementary-material"}. The red dash line denotes the significance level of 0.05.(B) Time course of tamoxifen (Tmx) treatment and tissue harvesting. Con indicates *Rpt3*^*f/f*^ mice and scKO indicates satellite cell-specific *Rpt3* knockout mice (*Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^).(C) Real-time RT-PCR was used to measure the mRNA expression of p53-related genes (*p53*, *p21*, *Cyclin D1*, and *Cdk4*) in *Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^ satellite cells treated with vehicle or 4OH-Tmx. Data represent means ± SEM (t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; n = 4--5 per group). AU, arbitrary units.(D) Immunoblotting analysis of relative protein levels of p53 targets in *Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^ satellite cells treated with vehicle or 4OH-Tmx.(E) Immunostaining for p53 (green) and DAPI (blue) in *Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^ satellite cells treated with vehicle or 4OH-Tmx. Arrows indicate p53-positive cells. Scale bar, 10  μm. The y axis shows the relative ratio of p53-positive cells. Data represent means ± SEM (t test: ^∗∗∗^p \< 0.001; n = 4 per group).(F) Time course analysis of *p53* siRNA knockdown and Tmx treatment.(G) Immunostaining for EdU (green) and DAPI (blue) in satellite cells treated with vehicle or 4OH-Tmx. Scale bar, 50  μm. The y axis shows the relative ratio of EdU-positive cells. Data represent means ± SEM (one-way ANOVA followed by the Bonferroni post hoc test: ^∗∗^p \< 0.01; NS, no significance; n = 4 per group).(H) Relative ratio of DAPI-positive cells. Data represent means ± SEM (one-way ANOVA followed by the Bonferroni post hoc test: ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.01; NS, no significance; n = 4--6 per group).See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

p53 is known to inhibit cell proliferation by both blocking cell-cycle progression and promoting apoptotic cell death ([@bib53]). As shown in [Figures 6](#fig6){ref-type="fig"}C, 6D, 6H, and 6I, suppression of cell proliferation and induction of apoptotic cell death was observed in *Rpt3*-scKO mice. We therefore examined whether the p53 pathway is involved in the regulation of *Rpt3*-scKO satellite cells. Satellite cells isolated from *Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^ mice were plated and then treated with 4OH-Tmx for 2 days to genetically delete *Rpt3* in satellite cells ([Figure 7](#fig7){ref-type="fig"}B). Expression of *Rpt3* was suppressed by 80% in *Rpt3* KO satellite-cell-derived myoblasts compared with that in control myoblasts ([Figure 7](#fig7){ref-type="fig"}C). As expected, levels of *p53*, as well as *p21*, which is a well-known p53-downstream target, were elevated, whereas *Cyclind1* and *Cdk4*, which are cell-cycle-related genes associated with *p53*, were suppressed in *Rpt3*-scKO satellite cell-derived myoblasts ([Figure 7](#fig7){ref-type="fig"}C). Consistent with mRNA levels, western blotting also demonstrated a dramatic increase in p53 protein and its phosphorylation (ser392) in *Rpt3*-scKO satellite cell-derived myoblasts ([Figure 7](#fig7){ref-type="fig"}D). p53-related proliferation is regulated by phosphorylated Rb, which was decreased in *Rpt3*-scKO satellite cell-derived myoblasts ([Figure 7](#fig7){ref-type="fig"}D). Moreover, based on immunohistochemistry, a greater than 20-fold increase in the number of p53-positive cells was confirmed in *Rpt3* KO satellite-cell-derived myoblasts as compared with those in controls ([Figure 7](#fig7){ref-type="fig"}E). These results demonstrate that *Rpt3* deletion in satellite-cell-derived myoblasts leads to the activation of p53 signaling in satellite cells.

Finally, to test if activation of p53 signaling is responsible for the inhibition of proliferation in *Rpt3*-scKO mice, we examined the effect of p53 silencing on *Rpt3*-null satellite cell-derived myoblasts. p53 knockdown was performed in C2C12 cells ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Two siRNAs were used and siRNA (\#2) showed greater than 90% reduction in *p53* gene expression ([Figures S7](#mmc1){ref-type="supplementary-material"}D--S7F) and was thus used for further experiments. Satellite cells isolated from *Pax7*^*CreERT2/+*^; *Rpt3*^*f/f*^ mice were plated and then treated with 4OH-Tmx for 2 days after *p53* siRNA transfection ([Figure 7](#fig7){ref-type="fig"}F). Importantly, the proliferative ability as well as the number of cells were both restored in *Rpt3*-null myoblasts when transfected with *p53* siRNA ([Figures 7](#fig7){ref-type="fig"}G, 7H, [S7](#mmc1){ref-type="supplementary-material"}G, and S7I), although the differentiation ability was not improved with *p53* knockdown ([Figures S7](#mmc1){ref-type="supplementary-material"}J and S7K). Taken together, these results show that knockdown of *p53* rescues defective proliferation in *Rpt3*-deficient primary myoblasts.

Discussion {#sec3}
==========

In this study, we report that the proteasome system is indispensable for the maintenance of muscle stem cells. Ablation of *Rpt3* in satellite cells impairs their ability to proliferate, survive, and differentiate, resulting in a severe defect in muscle regeneration. We also found that proteasome inactivation by *Rpt3* deficiency in primary myoblasts inhibits cell proliferation and induces apoptosis. Further, proteasome dysfunction conferred by satellite cell-specific *Rpt3* knockout induces p53 activation. Previously, it was determined that p53 inhibits cell proliferation by both blocking cell-cycle progression and promoting apoptotic cell death ([@bib53]). We also found that p53 knockdown rescued cell proliferation defects in *Rpt3*-deficient myoblasts.

The ubiquitin-proteasome system functions to degrade most long- and short-lived normal and abnormal intracellular proteins ([@bib9], [@bib18]). Especially in muscle, proteolysis by the ubiquitin-proteasome system is a major mechanism involved in myofibrillar protein degradation ([@bib2], [@bib20]). Therefore, when examining proteasome activity during regeneration, we found that both chymotrypsin-like and trypsin-like proteasome activities were increased 3 days after CTX injection, indicating that the early phase of muscle regeneration is associated with the activation of machinery involved in protein degradation. Furthermore, the accumulation of ubiquitinated proteins was also most accelerated on day 3 post injury, indicating that proteasome-related proteolysis was most enhanced at this time point. Interestingly, MYOD, which constitutes an important myogenic transcription factor for muscle regeneration ([@bib7], [@bib38]), was also particularly elevated on day 3 post injury. In a previous study, proteasome activity was found to be strongly correlated with proliferating cell nuclear antigen protein levels, suggesting that the proteasome plays a key role in myoblast proliferation ([@bib14]). Thus, it is suggested that enhancing the proteasome system during the early phase is an important event for normal muscle regeneration.

Previous studies have confirmed the absolute requirement for Pax7-positive satellite cells during muscle regeneration ([@bib27], [@bib37], [@bib40], [@bib52]). Our data support these findings that satellite cells are essential for muscle regeneration. When the number of satellite cells decreases, muscle regeneration fails. These data might indicate that the number of satellite cells is also important. However, other cells. such as mesoangioblasts and PW1+ interstitial cells, which contribute to regeneration, have been identified in muscle tissue ([@bib31], [@bib41]). Thus, we cannot exclude the possibility that the regenerative defect in *Rpt3*-scKO mice at day 14 after CTX injection could be improved after a long period of recovery by contributing to the myogenic potential of other cells involved in regeneration ([@bib31], [@bib41]).

Proteasome insufficiency due to *Rpt3* deficiency increased the protein levels of Cleaved-Caspase 3 and caused apoptosis. Furthermore, we performed immunoblotting analysis of Bax, Bak, Bcl-2, and Mcl-1 proteins related to apoptosis, but there was no significant change particularly (data not shown). A previous study reported that the proteasome inhibitor MG132 induces caspase-3-dependent apoptosis, and a caspase-3 inhibitor was found to reduce MG132-induced apoptosis in human mast cells ([@bib56]). Our data show that proteasome dysfunction by loss of Rpt3 is accompanied by apoptosis, which is at least due to enhancement of the caspase 3 activity. Therefore, in this study, it is considered that apoptosis in scKO primary myoblasts might be alleviated by the inhibition of Caspase 3.

There have been many previous studies on the association between the proteasome system and p53. Among these, one report suggested that the ubiquitination level of p53 is elevated after treatment with the proteasome inhibitor MG132 ([@bib28]), suggesting that this protein is degraded by the proteasome and that its stability is controlled by ubiquitin-dependent degradation. Consistent with these findings, we demonstrated p53 stability in primary myoblasts exhibiting proteasome dysfunction (via *Rpt3* ablation). p53 inhibits cell proliferation by both blocking cell-cycle progression and promoting apoptotic cell death ([@bib53]). In addition, proteasome inhibition has been shown to induce apoptosis in several different cell types ([@bib10], [@bib13], [@bib34]). Therefore, we hypothesized that proteasome dysfunction, mediated by *Rpt3* deletion, results in cell death and the inhibition of cell proliferation due to p53 hyperactivation. Because p53 is upregulated in *Rpt3*-deficient myoblasts, we examined whether knockdown of *p53* rescues the proliferation defects observed in *Rpt3*-deficient myoblasts. Importantly, we found that inhibition of *p53* successfully rescued these effects, indicating that the proteasome system in muscle stem cells regulates cell proliferation at least in part through p53.

Myogenesis is a complex process controlled by the spatiotemporal expression of many MRFs and transcription factors ([@bib5], [@bib35], [@bib54]). As myoblast differentiation proceeds, the timely synthesis and degradation of appropriate myogenic proteins are required, which suggests a significant role for adaptive proteolysis in the myogenic process. Indeed, previous studies have reported that the complex process of myogenic differentiation, which begins with cell-cycle arrest and ends with the fusion of individual myoblasts to form multinucleated myotubes, is related to the proteasome system ([@bib1], [@bib17], [@bib22]). In addition, inhibition or knockdown of the proteasome can block the fusion of myoblasts and inhibit differentiation ([@bib17], [@bib22]). Consistent with previous studies, proteasome dysfunction conferred by *Rpt3* deficiency was found to suppress the myogenic differentiation of primary myoblasts, suggesting that proper proteasome function is necessary for myogenic differentiation. In addition, it has been previously shown that p53 can promote muscle differentiation *in vitro* ([@bib19], [@bib36], [@bib43], [@bib45], [@bib55]). However, despite the presence of p53 observed in *Rpt3*-deficient primary myoblasts, *Rpt3* ablation was shown to suppress myogenic differentiation. This might be because p53 expression was excessive. Indeed, a 20-fold increase in p53-positive cells was observed in *Rpt3*-deficient myoblasts, as compared with that in controls, based on immunostaining. A recent study reported that tight control of p53 levels in myoblasts regulates the balance between differentiation and return to quiescence ([@bib16]), which could indicate appropriate expression of p53 during myogenic differentiation.

Satellite cells provide myonuclei for postnatal muscle growth and for maintenance and regeneration in adults ([@bib37], [@bib57]), indicating that the maintenance of satellite cells is essential for the functional homeostasis of skeletal muscle. Moreover, recent studies indicated that skeletal muscle disease is exacerbated by defective satellite cells ([@bib11]). Importantly, we found that proteasome dysfunction by loss of *Rpt3* in satellite cells leads to a dramatic depletion of the quiescent satellite cell pool approximately 2 weeks after knockout induction. Previous studies demonstrated that proteolysis by the proteasome is essential to maintain amino acid pools ([@bib44], [@bib49]). Although quiescent satellite cells are thought to be associated with very low turnover in steady state conditions ([@bib26]), minimal amino acid pools obtained from proteolysis by the proteasome system are necessary for the normal maintenance of cells. Therefore, proteasome dysfunction, conferred by *Rpt3* deficiency, might have resulted in serious consequences, depriving the cells of pooled resources for cellular maintenance. We hypothesize that satellite cell-specific *Rpt3* deficiency might have blocked the cellular "recycling system" that is essential for the maintenance of satellite cells; this question needs to be further examined.

*Rpt3* deficiency in primary myoblasts and *Rpt3* knockdown in a myoblast cell line resulted in a decrease in proteasome activity, leading to apoptotic cell death. There are several reports showing the relationship between proteasomal activity and aging, including lifespan. During aging, proteasomal activity is decreased in several tissues, such as the brain ([@bib58]), liver ([@bib12], [@bib21]), heart ([@bib6]), and muscle ([@bib15]). Overexpression of proteasome subunits in yeast and *Caenorhabditis elegans* has been shown to lead to an increase in proteasome activity as well as prolonged lifespan ([@bib8], [@bib50]), whereas flies and mice with a genetic decrease in proteasome activity have a shortened lifespan ([@bib47], [@bib48]). Previously, we have also reported a shortened lifespan even in muscle-specific *Rpt3*-knockout mice ([@bib25]). Taken together, these data suggest that there is a close relationship between the proteasome system and aging *in vivo* and *in vitro*. Whether adult somatic stem cells also have enhanced proteasome activity remains to be elucidated, but the maintenance of this activity might critically affect organismal aging ([@bib51]). Therefore, our findings using muscle stem cells will lead to a detailed understanding of proteolysis and its associated molecular mechanisms in muscle stem cells. Our results show that the ubiquitin-proteasome system is indispensable for the maintenance of muscle stem cells. Further study is needed to understand the role of stem cells in various physiological processes involving the proteasome system; however, this work provides the fundamentals for understanding the regulation of proteolysis in muscle stem cells.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Satellite cells were cultured in GM (DMEM supplemented with 30% fetal bovine serum, 1% chick embryo extract, 10 ng/mL basic fibroblast growth factor, and 1% penicillin-streptomycin) on culture dishes coated with Matrigel (BD Biosciences). Myogenic differentiation was induced in DM (DMEM supplemented with 5% horse serum and 1% penicillin-streptomycin). For *in vitro* genetic deletion, 4-OH Tmx (1 μM) was added to culture medium for 2 days to induce Cre-mediated deletion.

Mouse C2C12 myoblasts were cultured in GM (DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin). The cells were transfected with 30 nM siRNA using Lipofectamine RNAiMAX (Invitrogen).

Single Fiber Isolation {#sec4.2}
----------------------

Individual myofibers were isolated from the EDL muscle as we described previously ([@bib23], [@bib33]). In brief, EDL myofibers were digested using 0.2% type I collagenase (Worthington) in DMEM for 90 min at 37°C with 5% CO~2~. Muscles were mechanically dissociated and then washed five times to eliminate debris and contaminating cells. For immunohistochemical analysis, EDL myofibers were immediately fixed using 4% paraformaldehyde (PFA, Wako) in PBS.
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